Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy

PLoS ONE

Volumn 12, Issue 9, 2017, Pages

  Kwiatkowski, Sam C ^a   Guerrero, Paola A ^a   Hirota, Shinya ^a   Chen, Zhihua ^a   Morales, John E ^a   Aghi, Manish ^b   McCarty, Joseph H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; NEUROPILIN 1; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TGF BETA SIGNALING; ANIMAL; BRAIN; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOBLASTOMA; HEK293 CELLS; HUMANS; MALE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEUROPILIN-1; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85029793094     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0185065     Document Type: Article

References (52)

1. Louis DN. Molecular pathology of malignant gliomas. Annual review of pathology. 2006; 1:97–117. https://doi.org/10.1146/annurev.pathol.1.110304.100043 PMID: 18039109.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21(21):2683–710. https://doi.org/10.1101/gad.1596707 PMID: 17974913.
3. Sayegh ET, Kaur G, Bloch O, Parsa AT. Systematic review of protein biomarkers of invasive behavior in glioblastoma. Molecular neurobiology. 2014; 49(3):1212–44. https://doi.org/10.1007/s12035-013-8593-5 PMID: 24271659.
4. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8(8):610–22. https://doi.org/10.1038/nrn2175 PMID: 17643088.
5. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013; 19(7):1773–83. https://doi.org/10.1158/1078-0432.CCR-12-1281 PMID: 23307858
6. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer cell. 2012; 22(1):21–35. https://doi.org/10.1016/j.ccr.2012.05.037 PMID: 22789536
7. Ellis LM, Reardon DA. Cancer: The nuances of therapy. Nature. 2009; 458(7236):290–2. https://doi.org/10.1038/458290a PMID: 19295595.
8. McCarty JH. Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET? Clin Cancer Res. 2013; 19(7):1631–3. https://doi.org/10.1158/1078-0432.CCR-13-0051 PMID: 23403631
9. Rich JN. The role of transforming growth factor-beta in primary brain tumors. Front Biosci. 2003; 8: e245–60. PMID: 12456378.
10. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007; 11(2):147–60. https://doi.org/10.1016/j.ccr.2006.11.023 PMID: 17292826.
11. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, et al. Expression of TGFbeta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer. 2000; 89(3):251–8. PMID: 10861501.
12. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009; 19(1):116–27. https://doi.org/10.1038/cr.2008.326 PMID: 19114994.
13. Wrana JL. Signaling by the TGFbeta superfamily. Cold Spring Harbor perspectives in biology. 2013; 5 (10):a011197. https://doi.org/10.1101/cshperspect.a011197 PMID: 24086041
14. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell. 1997; 90(4):739–51. PMID: 9288753.
15. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92 (6):735–45. PMID: 9529250.
16. Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene. 2007; 26(38):5577–86. https://doi.org/10.1038/sj.onc.1210348 PMID: 17369861
17. Hillman RT, Feng BY, Ni J, Woo WM, Milenkovic L, Hayden Gephart MG, et al. Neuropilins are positive regulators of Hedgehog signal transduction. Genes & development. 2011; 25(22):2333–46. https://doi.org/10.1101/gad.173054.111 PMID: 22051878
18. Rizzolio S, Rabinowicz N, Rainero E, Lanzetti L, Serini G, Norman J, et al. Neuropilin-1-dependent regulation of EGF-receptor signaling. Cancer Res. 2012; 72(22):5801–11. https://doi.org/10.1158/00085472.CAN-12-0995 PMID: 22986738.
19. Muhl L, Folestad EB, Gladh H, Wang Y, Moessinger C, Jakobsson L, et al. Neuropilin 1 binds platelet-derived growth factor (PDGF)-D and is a co-receptor in PDGF-D/PDGF receptor beta signaling. Journal of cell science. 2017. https://doi.org/10.1242/jcs.200493 PMID: 28254885.
20. Kofler N, Simons M. The expanding role of neuropilin: regulation of transforming growth factor-beta and platelet-derived growth factor signaling in the vasculature. Current opinion in hematology. 2016; 23 (3):260–7. https://doi.org/10.1097/MOH.0000000000000233 PMID: 26849476
21. Cao Y, Szabolcs A, Dutta SK, Yaqoob U, Jagavelu K, Wang L, et al. Neuropilin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. J Biol Chem. 2010; 285(41):31840–8. https://doi.org/10.1074/jbc.M110.151696 PMID: 20675371
22. Glinka Y, Prud’homme GJ. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol. 2008; 84(1):302–10. https://doi.org/10.1189/jlb.0208090 PMID: 18436584
23. Glinka Y, Stoilova S, Mohammed N, Prud’homme GJ. Neuropilin-1 exerts co-receptor function for TGFbeta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis. 2011; 32(4):613–21. https://doi.org/10.1093/carcin/bgq281 PMID: 21186301.
24. Aspalter IM, Gordon E, Dubrac A, Ragab A, Narloch J, Vizan P, et al. Alk1 and Alk5 inhibition by Nrp1 controls vascular sprouting downstream of Notch. Nature communications. 2015; 6:7264. https://doi.org/10.1038/ncomms8264 PMID: 26081042
25. Hirota S, Clements TP, Tang LK, Morales JE, Lee HS, Oh SP, et al. Neuropilin 1 balances beta8 integrin-activated TGFbeta signaling to control sprouting angiogenesis in the brain. Development. 2015; 142 (24):4363–73. https://doi.org/10.1242/dev.113746 PMID: 26586223
26. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer cell. 2007; 11(1):53–67. https://doi.org/10.1016/j.ccr.2006.10.018 PMID: 17222790.
27. Reyes SB, Narayanan AS, Lee HS, Tchaicha JH, Aldape KD, Lang FF, et al. alphavbeta8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. Molecular biology of the cell. 2013; 24(4):474–82. https://doi.org/10.1091/mbc.E12-07-0521 PMID: 23283986
28. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462–77. https://doi.org/10.1016/j.cell.2013.09.034 PMID: 24120142
29. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3):157–73. https://doi.org/10.1016/j.ccr.2006.02.019 PMID: 16530701.
30. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98–110. https://doi.org/10.1016/j.ccr.2009.12.020 PMID: 20129251
31. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010; 16(2):461–73. https://doi.org/10.1158/1078-0432.CCR-09-1983 PMID: 20068105
32. Kang JS, Liu C, Derynck R. New regulatory mechanisms of TGF-beta receptor function. Trends in cell biology. 2009; 19(8):385–94. https://doi.org/10.1016/j.tcb.2009.05.008 PMID: 19648010.
33. Koch S, van Meeteren LA, Morin E, Testini C, Westrom S, Bjorkelund H, et al. NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev Cell. 2014; 28(6):633–46. https://doi.org/10.1016/j.devcel.2014.02.010 PMID: 24656741.
34. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS letters. 2006; 580(12):2811–20. https://doi.org/10.1016/j.febslet.2006.04.033 PMID: 16678165.
35. Prahst C, Heroult M, Lanahan AA, Uziel N, Kessler O, Shraga-Heled N, et al. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J Biol Chem. 2008; 283(37):25110–4. https://doi.org/10.1074/jbc.C800137200 PMID: 18628209
36. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(16):8502–7. PMID: 8710899
37. van Meeteren LA, Goumans MJ, ten Dijke P. TGF-beta receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol. 2011; 12(12):2108–20. PMID: 21619534.
38. McCarty JH. Cell adhesion and signaling networks in brain neurovascular units. Curr Opin Hematol. 2009; 16(3):209–14. https://doi.org/10.1097/MOH.0b013e32832a07eb PMID: 19318941
39. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer research. 2013; 73(10):3145–54. https://doi.org/10.1158/0008-5472.CAN-13-0011 PMID: 23644530
40. Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer immunology, immunotherapy: CII. 2014; 63(2):81–99. https://doi.org/10.1007/s00262-013-1500-0 PMID: 24263240.
41. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013; 19(16):4392–403. https://doi.org/10.1158/1078-0432.CCR-12-1557 PMID: 23804423.
42. Matkar PN, Singh KK, Rudenko D, Kim YJ, Kuliszewski MA, Prud’homme GJ, et al. Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma. Oncotarget. 2016; 7(43):69489–506. https://doi.org/10.18632/oncotarget.11060 PMID: 27542226
43. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature reviews Cancer. 2008; 8(8):592–603. https://doi.org/10.1038/nrc2442 PMID: 18650835
44. Patil V, Pal J, Somasundaram K. Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget. 2015; 6(41):43452–71. https://doi.org/10.18632/oncotarget.6171 PMID: 26496030
45. Tchaicha JH, Mobley AK, Hossain MG, Aldape KD, McCarty JH. A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene. 2010; 29 (31):4460–72. https://doi.org/10.1038/onc.2010.199 PMID: 20531304
46. Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, McCarty JH. Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res. 2011; 71(20):6371–81. https://doi.org/10.1158/0008-5472.CAN-11-0991 PMID: 21859829
47. McCarty JH, Lacy-Hulbert A, Charest A, Bronson RT, Crowley D, Housman D, et al. Selective ablation of {alpha}v integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal degeneration and premature death. Development. 2004. https://doi.org/10.1242/dev.01551 PMID: 15576410.
48. McCarty JH, Monahan-Earley RA, Brown LF, Keller M, Gerhardt H, Rubin K, et al. Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol Cell Biol. 2002; 22(21):7667–77. https://doi.org/10.1128/MCB.22.21.7667-7677.2002 PMID: 12370313.
49. Mu Z, Yang Z, Yu D, Zhao Z, Munger JS. TGFbeta1 and TGFbeta3 are partially redundant effectors in brain vascular morphogenesis. Mech Dev. 2008; 125(5–6):508–16. Epub 2008/03/18. https://doi.org/10.1016/j.mod.2008.01.003 PMID: 18343643.
50. Proctor JM, Zang K, Wang D, Wang R, Reichardt LF. Vascular development of the brain requires beta8 integrin expression in the neuroepithelium. J Neurosci. 2005; 25(43):9940–8. https://doi.org/10.1523/JNEUROSCI.3467-05.2005 PMID: 16251442.
51. Zhu J, Motejlek K, Wang D, Zang K, Schmidt A, Reichardt LF. beta8 integrins are required for vascular morphogenesis in mouse embryos. Development. 2002; 129(12):2891–903. PMID: 12050137.
52. Nguyen HL, Lee YJ, Shin J, Lee E, Park SO, McCarty JH, et al. TGF-beta signaling in endothelial cells, but not neuroepithelial cells, is essential for cerebral vascular development. Laboratory investigation. 2011;in press. Epub 2011/08/31. https://doi.org/10.1038/labinvest.2011.124 PMID: 21876535.